Michael Crump Selected Research

Non-Hodgkin Lymphoma (Lymphosarcoma)

1/2021	Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
10/2019	DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
10/2019	Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients.
10/2017	Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
10/2016	Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma.
10/2015	Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
8/2015	Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12.
6/2015	Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab.
11/2014	Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma.
5/2012	A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Crump Research Topics

Disease

32	Lymphoma (Lymphomas) 01/2023 - 11/2003
23	Neoplasms (Cancer) 12/2022 - 08/2002
20	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 10/2023 - 10/2002
20	Hodgkin Disease (Hodgkin's Disease) 12/2022 - 12/2003
18	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021 - 08/2002
12	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/2020 - 08/2011
10	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 12/2023 - 02/2002
7	B-Cell Lymphoma (Lymphoma, B Cell) 10/2021 - 10/2002
7	Breast Neoplasms (Breast Cancer) 08/2011 - 04/2002
7	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2010 - 01/2002
6	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2018 - 03/2006
6	Disease Progression 01/2016 - 05/2003
5	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/2021 - 01/2009
4	Neutropenia 01/2018 - 08/2009
4	Thrombocytopenia (Thrombopenia) 10/2016 - 08/2009
4	Leukemia 04/2010 - 01/2002
3	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2022 - 03/2019
3	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 10/2019 - 11/2003
3	Pathologic Complete Response 01/2016 - 10/2005
3	Alzheimer Disease (Alzheimer's Disease) 03/2011 - 01/2010
2	Melanoma (Melanoma, Malignant) 05/2019 - 10/2017
2	Pneumonia (Pneumonitis) 06/2015 - 08/2011
2	Infections 08/2011 - 10/2002
2	Anemia 08/2009 - 01/2009
1	COVID-19 10/2023
1	Testicular Germ Cell Tumor 01/2023
1	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 01/2023
1	Sarcopenia 01/2022
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 10/2021
1	Inflammation (Inflammations) 10/2021
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2018
1	Exanthema (Rash) 01/2018
1	Proteinuria 10/2017
1	Nephrotic Syndrome (Syndrome, Nephrotic) 10/2017

Drug/Important Bio-Agent (IBA)

32	Rituximab (Mabthera)FDA Link 10/2023 - 02/2002
12	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 10/2004
10	Gemcitabine FDA Link 01/2023 - 10/2004
9	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2023 - 10/2002
9	Dexamethasone (Maxidex)FDA LinkGeneric 01/2023 - 10/2004
8	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2023 - 11/2003
7	Guanosine Diphosphate (GDP)IBA 01/2023 - 01/2006
6	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2023 - 03/2007
6	Prednisone (Sone)FDA LinkGeneric 10/2023 - 10/2002
6	Vincristine (Oncovin)FDA LinkGeneric 10/2023 - 10/2002
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 05/2012
4	Bendamustine Hydrochloride FDA Link 11/2021 - 01/2018
4	obinutuzumabIBA 03/2019 - 05/2012
4	Bortezomib (Velcade)FDA Link 05/2013 - 03/2011
3	Brentuximab VedotinIBA 12/2020 - 01/2018
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 10/2010
3	Bleomycin (Blenoxane)FDA LinkGeneric 11/2017 - 03/2007
3	Vinblastine (Vinblastine Sulfate)FDA Link 02/2012 - 02/2006
3	Carmustine (FIVB)FDA Link 04/2010 - 04/2005
2	Methotrexate (Mexate)FDA LinkGeneric 01/2023 - 11/2003
2	Amyloid (Amyloid Fibrils)IBA 12/2021 - 01/2011
2	Monoclonal AntibodiesIBA 03/2019 - 10/2015
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2017 - 05/2012
2	Histones (Histone)IBA 01/2017 - 01/2016
2	Histone Deacetylase InhibitorsIBA 01/2017 - 01/2016
2	EnzymesIBA 01/2016 - 08/2002
2	temsirolimus FDA Link 01/2015 - 08/2009
2	TOR Serine-Threonine KinasesIBA 01/2015 - 08/2009
2	Dacarbazine (DIC)FDA LinkGeneric 02/2012 - 03/2007
2	Insulysin (Insulin-Degrading Enzyme)IBA 01/2011 - 01/2010
2	Messenger RNA (mRNA)IBA 01/2011 - 01/2010
2	Etoposide (VP 16)FDA LinkGeneric 01/2006 - 08/2002
1	Chimeric Antigen ReceptorsIBA 10/2023
1	polatuzumab vedotinIBA 10/2023
1	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 01/2023
1	Alkylating AgentsIBA 12/2021
1	Proteasome InhibitorsIBA 12/2021
1	ibrutinibIBA 11/2021
1	Capsules (Microcapsules)IBA 10/2021
1	FibrinIBA 10/2021
1	Anaplastic Lymphoma KinaseIBA 10/2021
1	glofitamabIBA 01/2021
1	venetoclaxIBA 12/2020
1	duvelisibIBA 10/2019
1	Interleukin-2 (IL2)IBA 05/2019
1	AntibodiesIBA 03/2019
1	romidepsin (FK228)FDA Link 01/2019
1	IpilimumabIBA 10/2017
1	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2017

Therapy/Procedure

46	Therapeutics 12/2023 - 01/2002
45	Drug Therapy (Chemotherapy) 01/2023 - 01/2002
17	Stem Cell Transplantation 12/2022 - 02/2002
12	Radiotherapy 01/2019 - 10/2002
7	Salvage Therapy 10/2023 - 01/2006
4	Transplantation 01/2017 - 11/2003
3	Immunotherapy 10/2017 - 02/2002
3	Hematopoietic Stem Cell Transplantation 08/2011 - 01/2006
3	Induction Chemotherapy 10/2005 - 11/2003
3	Adjuvant Chemotherapy 04/2005 - 08/2003
2	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2004 - 02/2003
1	Combination Drug Therapy (Combination Chemotherapy) 01/2022
1	Breast Implants (Breast Implant) 10/2021
1	Hematopoietic Stem Cell Mobilization 01/2020
1	Organ Transplantation 01/2020
1	Radioimmunotherapy 10/2019
1	Cell- and Tissue-Based Therapy (Cell Therapy) 05/2019